Novel oral anticoagulants: Focus on the direct factor Xa inhibitor darexaban

Expert Opinion on Investigational Drugs

Volumn 21, Issue 7, 2012, Pages 1057-1064

  Apostolakis, Stavros ^a   Lip, Gregory Y H ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Clinical development; Darexaban; Factor Xa inhibitors; Oral anticoagulants; YM150

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; DAREXABAN; ENOXAPARIN; THROMBIN INHIBITOR; WARFARIN;

ACUTE CORONARY SYNDROME; ARTICLE; BLEEDING; COMPARATIVE STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; HEART MUSCLE ISCHEMIA; HIP ARTHROPLASTY; HUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); STROKE; VENOUS THROMBOEMBOLISM;

ADMINISTRATION, ORAL; ANIMALS; ANTICOAGULANTS; AZEPINES; BENZAMIDES; BLOOD COAGULATION; CLINICAL TRIALS AS TOPIC; CORONARY ARTERY DISEASE; FACTOR XA; HUMANS; SECONDARY PREVENTION; THROMBIN; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 84862276529     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2012.689286     Document Type: Article

References (32)

1. Gaziano MJ. Global burden of cardiovascular disease. In: Braunwald E, editor. Heart Disease. 7th edition. Elsevier Saunders; Philadelphia 2005. p. 1-19
2. Apostolakis S, Lip GY, Lane DA, Shantsila E. The quest for new anticoagulants: from clinical development to clinical practice. Cardiovasc Ther 2011;29:e12-22
3. Carson JL. Subcutaneous unfractionated heparin vs low-molecular-weight heparin for acute thromboembolic disease: issues of efficacy and cost. JAMA 2006;296:991-3 (Pubitemid 44285377)
4. Aujesky D, Smith KJ, Cornuz J, Roberts MS. Cost-effectiveness of low-molecular-weight heparin for treatment of pulmonary embolism. Chest 2005;128:1601-10 (Pubitemid 41324453)
5. Feinberg WM, Blackshear JL, Laupacis A, et al Prevalence, age distribution and gender of patients with atrial fibrillation. Arch Intern Med 1995;155:469-73
6. Krahn AD, Manfreda J, Tate RB, et al. The natural history of atrial fibrillation: incidence, risk factors and prognosis in the Manitoba follow-up study. Am J Med 1995;98:476-84
7. Torbicki A, Perrier A, Konstantinides S, et al. ESC Committee for Practice Guidelines (CPG). Guidelines on thediagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J 2008;29:2276-315
8. Monroe DM, Hoffman M. What does it take to make the perfect clot? Arterioscler Thromb Vasc Biol 2006;26:41-8 (Pubitemid 43732226)
9. Monroe DM, Hoffman M, Roberts HR. Platelets and thrombin generation. Arterioscler Thromb Vasc Biol 2002;22:1381-9
10. Tulinsky A. Molecular interactions of thrombin. Semin Thromb Hemost 1996;22:117-24 (Pubitemid 26239903)
11. Liaw PCY, Becker DL, Stafford AR, et al. Molecular basis for the susceptibility of fibrin-bound thrombin to inactivation by heparin cofactor II in the presence of dermatan sulfate but not heparin. J Biol Chem 2001;276:20959-65
12. Di Nisio M, Middeldorp S, Buller HR. Direct thrombin inhibitors. N Engl J Med 2005;353:1028-40 (Pubitemid 41262337)
13. Blech S, Ebner T, Ludwig-Schwellinger E, et al. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 2008;36:386-99 (Pubitemid 351185753)
14. Feistritzer C, Lenta R, Riewald M. Protease-activated receptors-1 and-2 can mediate endothelial barrier protection: role in factor Xa signaling. J Thromb Haemost 2005;3:2798-805 (Pubitemid 41819810)
15. Khoo CW, Tay KH, Shantsila E, Lip GY. Novel oral anticoagulants. Int J Clin Pract 2009;63:630-41
16. Iwatsuki Y, Sato T, Moritani Y, et al Biochemical and pharmacological profile of darexaban, an oral direct factor Xa inhibitor. Eur J Pharmacol 2011;673:49-55
17. Iwatsuki Y, Shigenaga T, Moritani Y, et al. Biochemical and pharmacological profiles of YM150, an oral direct factor Xa inhibitor. Blood 2006;108:273A.
18. Saitoh M, Kaku S, Funatsu T, et al Comparison of YM150, an oral, direct factor Xa inhibitor, with other antithrombotic agents in rodent venous and arterial thrombosis models. Blood 2007;110:374A.
19. Eriksson BI, Turpie AG, Lassen MR, et al; ONYX study group. A dose escalation study of YM150, an oral direct factor Xa inhibitor, in the prevention of venous thromboembolism in elective primary hip replacement surgery. J Thromb Haemost 2007;5:1660-5 (Pubitemid 47091408)
20. Eriksson BI, Turpie AG, Lassen MR, et al; ONYX-2 study group. Prevention of venous thromboembolism with an oral factor Xa inhibitor, YM150, after total hip arthroplasty. A dose finding study (ONYX-2). J Thromb Haemost 2010;8:714-21
21. Turpie AGG, Lip GYH, Minematsu K, et al. Safety and tolerability of YM150 in subjects with non-valvular atrial fibrillation: a Phase II Study. Eur Heart J 2010;21(Suppl 1):173
22. Lip GYH, Halperin JL, Petersen P, et al. Safety and tolerability of the oral factor Xa inhibitor, YM150 versus warfarin in 1297 patients with non-valvular atrial fibrillation: a dose confirmation study (OPAL-2). J Thromb Hemost 2011;9(Suppl 2):748
23. Steg PG, Mehta SR, Jukema JW, et al. RUBY-1 Investigators. RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome. Eur Heart J 2011;32:2541-54.
24. APPRAISE Steering Committee and Investigators, Alexander JH, Becker RC, Bhatt DL, et al. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation 2009;119:2877-85
25. Alexander JH, Lopes RD, James S, et al APPRAISE-2 Investigators. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 2011;365:699-708
26. Oldgren J, Budaj A, Granger CB, et al. RE-DEEM Investigators. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J 2011;32:2781-9
27. Mega JL, Braunwald E, Mohanavelu S, et al. ATLAS ACS-TIMI 46 study group. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet 2009;374:29-38
28. Mega JL, Braunwald E, Wiviott SD, et al. ATLAS ACS 2-TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012;366:9-19.
29. Murphy SA, Antman EM, Wiviott SD, et al; TRITON-TIMI 38 Investigators. Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial. Eur Heart J 2008;29:2473-9
30. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2010;361:1045-57
31. Younis HS, Crosby J, Huh JI, et al. Antisense inhibition of coagulation factor XI prolongs APTT without increased bleeding risk in cynomolgus monkeys. Blood 2012;119:2401-8
32. Cohen MG, Purdy DA, Rossi JS, et al. First clinical application of an actively reversible direct factor IXa inhibitor as an anticoagulation strategy in patients undergoing percutaneous coronary intervention. Circulation 2010;122:614-22